PerMe

Company Overview

Snapshot

Founded in May 2022 by Yoav Rapaport and Igal Chertkow, PerMe operates with 11–50 employees. The company has raised $2 million across two funding rounds.

Business overview

PerMe is a deep-tech digital health platform focused on disruptive innovation in home DNA testing. The company develops a novel IP to convert biological samples into digital information in real-time using an affordable device, eliminating the need for traditional laboratories. PerMe's software generates health recommendations and facilitates telehealth consultations from biological data, with plans to apply advanced data analytics and AI/ML to collected big data for healthcare innovation, disease understanding, and new medicine discovery. It operates within the Health Tech & Life Sciences sector, specifically in Digital Healthcare, with applications in Patient Remote Monitoring and Digital Medical Diagnostics.

Strategic signal

In November 2024, PerMe was highlighted by CTech for its revolutionary approach to DNA diagnostics, signaling strong market validation and potential for significant disruption in the health tech industry. This recognition underscores the company's innovative technology and its immediate forward trajectory in transforming how DNA-based health insights are accessed and utilized.

Company Intelligence Q&A

Who founded PerMe?

PerMe was founded by Yoav Rapaport and Igal Chertkow in May 2022.

What is PerMe's core technology?

PerMe's core technology involves a novel IP that converts biological samples into digital information in real-time using an affordable device, bypassing the need for traditional laboratories. This deep-tech digital health platform aims to provide health recommendations and telehealth consultations based on DNA data.

What is the total capital raised by PerMe?

PerMe has raised a total of $2 million across two funding rounds.

What recognition has PerMe received recently?

In November 2024, PerMe was featured by CTech for its revolutionary advancements in DNA diagnostics, highlighting its innovative technology and market potential.